These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3260564)

  • 1. Anti-tumour efficacy of IL-1 and IL-2.
    Bubeník J; Indrová M; Holán V
    Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
    Bubeník J; Indrová M; Toulcová A
    Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
    Símová J; Bubeník J; Voitenok NN; Gren E
    Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
    Silagi S; Schaefer AE
    J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
    Bubeník J; Kieler J; Indrová M
    Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
    Indrová M; Bubeník J; Toulcová A
    Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
    Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
    Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
    Wang C; Chai L; Zhu G
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active suppression of the proliferative response to interleukin-2 in tumour-bearing mice.
    Zajícová A; Holán V
    Folia Biol (Praha); 1990; 36(6):301-11. PubMed ID: 2279584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy using local interleukin 2 administration.
    Bubeník J; Indrová M
    Immunol Lett; 1987 Dec; 16(3-4):305-9. PubMed ID: 3502122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.